Breaking News
Sort by:
Top Post
Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine
Google Cloud has announced two new AI-powered life sciences solutions to accelerate drug discovery and […]
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
Takeda has announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 […]
Global Sarcoma Therapy Now Approved For New Zealand Patients
Independent biopharmaceutical company, Specialised Therapeutics (ST), is pleased to announce that its portfolio therapy to […]
Chiesi Global Rare Diseases Announces FDA Approval of Lamzede®(velmanase alfa-tycv) for Alpha-Mannosidosis
Chiesi Global Rare Diseases announced today that the US Food and Drug Administration (FDA) has […]
Aqilion announces Pre-clinical Licensing and Strategic Research Collaboration Agreement with Merck
Aqilion today announced an exclusive license and strategic research collaboration with Merck to discover, develop […]
Mirum Pharmaceuticals Submits Supplemental New Drug Application for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
Mirum Pharmaceuticals has announced that it has submitted a supplemental New Drug Application (sNDA) for […]
Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy
Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called […]
LegoChem Biosciences Signs License Agreement to Acquire First-in-class Antibody From Elthera
LegoChem Biosciences announced on February 13, 2023 a license agreement with Elthera AG, a biotechnology […]
FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)
Pfizer has announced that the United States Food and Drug Administration (FDA) approved its supplemental […]
U.S. FDA Grants Regular Approval for Jemperli for the Treatment of Patients with Recurrent or Advanced Mismatch Repair-deficient Endometrial Cancer
GSK reports that the US Food and Drug Administration (FDA) granted full approval for Jemperli (dostarlimab-gxly) […]
FDA Grants Regenerative Medicine Advanced Therapy Designation for Rexlemestrocel-L in Chronic Low Back Pain
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more